Telitacicept Treatment Refractory Lupus Nephritis: A Case Report

被引：3

作者：

Li, Sijia ^{[1
]}

Deng, Shuting ^{[2
]}

Wen, Sichun ^{[1
]}

Peng, Siqi ^{[1
]}

Jiang, Nan ^{[1
]}

Li, Bohou ^{[1
]}

Chen, Boxi ^{[1
]}

Yuan, Ye ^{[1
]}

Wu, Qiong ^{[1
]}

Tao, Yiming ^{[1
]}

Ma, Jianchao ^{[1
]}

Lin, Ting ^{[1
]}

Wen, Feng ^{[1
]}

Li, Zhuo ^{[1
]}

Dai, Hao ^{[1
]}

Huang, Renwei ^{[1
]}

Feng, Zhonglin ^{[1
]}

Li, Zhilian ^{[1
]}

Liu, Shuangxin ^{[1
]}

Xu, Lixia ^{[1
]}

机构：

[1] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Nephrol, Guangzhou, Peoples R China

[2] South China Univ Technol, Sch Med, Guangzhou, Peoples R China

来源：

CASE REPORTS IN NEPHROLOGY AND DIALYSIS | 2024年 / 14卷 / 01期

关键词：

Systemic lupus erythematosus; Refractory lupus nephritis; Telitacicept; Biologics; Treatment; MANAGEMENT;

D O I：

10.1159/000538033

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Refractory lupus nephritis (LN) causes kidney disease progression and increases the risk of loss of renal function. Due to the high specificity and few side effects of biological agents, they are recommended for the treatment of systemic lupus erythematosus. There are few data on telitacicept for the treatment of refractory LN. Case Presentation: Here, we report the efficacy and safety of telitacicept in the treatment of refractory LN in a 25-year-old female patient. This patient with refractory lupus developed Pneumocystis jirovecii pneumonia while using multitargeted therapy, and the patient's urine protein was rapidly relieved after telitacicept combination with low-dose mycophenolate mofetil (MMF). Conclusion: This result suggests that telitacicept has a positive effect on refractory LN with no significant side effects. Further reports and a registry are necessary to confirm that telitacicept with low-dose MMF should be preferred in refractory LN.

引用

页码：42 / 47

页数：6

共 50 条

[41] Telitacicept for systemic lupus erythematosus with post-surgical papillary thyroid carcinoma: A case report
Tan, Jinhui
Huang, Hai
Tan, Linghua
Li, Bo
BIOMEDICAL REPORTS, 2025, 22 (03)
[42] When should targeted therapies be used in the treatment of lupus nephritis: Early in the disease course or in refractory patients?
Parodis, Ioannis
Depascale, Roberto
Doria, Andrea
Anders, Hans -Joachim
AUTOIMMUNITY REVIEWS, 2024, 23 (01)
[43] LUPUS, SICCA SYNDROME, AND CHRONIC INTERSTITIAL NEPHRITIS - REPORT OF A CASE
BLANCHE, P
SICARD, D
REVUE DU RHUMATISME, 1992, 59 (11): : 755 - 756
[44] Update on lupus nephritis
Schneider, M.
Schwarting, A.
Chehab, G.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2024, 83 (06): : 447 - 454
[45] Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus
Yang, Tzu-Han
Wu, Tsai-Hung
Chang, Yuh-Lih
Liao, Hsien-Tzung
Hsu, Chia-Chen
Tsai, Chang-Youh
Chou, Yueh-Ching
CLINICAL NEPHROLOGY, 2018, 89 (04) : 277 - 285
[46] Successful treatment of refractory acute lupus haemophagocytic syndrome using rituximab: a case report
Tomofuji, Yoshihiko
Ishikawa, Yuichi
Hattori, Koto
Fujiwara, Michio
Kita, Yasuhiko
MODERN RHEUMATOLOGY CASE REPORTS, 2020, 4 (02) : 222 - 228
[47] Management of refractory lupus nephritis: challenges and solutions
Yo, J. H.
Barbour, T. D.
Nicholls, K.
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2019, 11 : 179 - 188
[48] Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: Report of a case
Uthman, Imad
Taher, Ali
Abbas, Ossama
Menassa, Janine
Ghosn, Samer
DERMATOLOGY, 2008, 216 (03) : 257 - 259
[49] The safety of pharmacological treatment options for lupus nephritis
Velo-Garcia, Alba
Ntatsaki, Eleana
Isenberg, David
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) : 1041 - 1054
[50] Lupus nephritis: new progress in diagnosis and treatment
Yu, Chen
Li, Ping
Dang, Xin
Zhang, Xuan
Mao, Yonghui
Chen, Xiangmei
JOURNAL OF AUTOIMMUNITY, 2022, 132

← 1 2 3 4 5 →